Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival in a population-based cohort.
INTRODUCTION
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative modality for selected patients with hematologic malignancies, nonmalignant hematologic disorders, immunodeficiencies, and genetic disorders (ie, storage diseases and hemoglobinopathies). Over the past four decades, the practice of alloHCT has evolved, with new sources of hematopoietic cells (peripheral blood and umbilical cord blood [UCB]), 1 the advent of reducedintensity and nonmyeloablative conditioning regimens that provide a curative option to patients who otherwise would not have undergone alloHCT in the past, 2-6 the introduction of tacrolimus and mycophenolate mofetil for graft-versus-host disease (GVHD) prophylaxis, 7, 8 higher resolution and number of loci tested for HLA matching, 9 and increased number and ethnic diversity of the unrelated-donor pool.
10, 11 The latter two have improved donor HLA matching and selection. Simultaneously, there have been major changes to cancer treatments, with the development of monoclonal antibodies (rituximab, alemtuzumab), tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib), immunomodulatory drugs (thalidomide, lenalidomide), small-molecule inhibitors (bortezomib, sirolimus, temsirolimus, everolimus), hypomethylating agents
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(azacitidine, decitabine), and other novel therapies. These changing treatment paradigms may have affected referral patterns and indications for alloHCT. 12 In addition, several nonmedical practices have affected alloHCT referrals (eg, varying insurance coverage of alloHCT for multiple myeloma [MM] and myelodysplastic syndrome [MDS] ). [13] [14] [15] [16] The existence of the Center for International Blood and Marrow Transplant Research (CIBMTR), a worldwide registry of alloHCT, makes it possible to study whether and how the use of alloHCT in the therapy of cancer and other disorders has changed over time. The study reported herein describes the changes in the alloHCT patient population and their overall survival (OS) rates over a 12-year period.
PATIENTS AND METHODS

About the CIBMTR
The CIBMTR is a research affiliation of the International Bone Marrow Transplant Registry, Autologous Blood and Marrow Transplant Registry, and National Marrow Donor Program (NMDP). Established in 2004, it comprises a voluntary working group of more than 450 transplantation centers worldwide that contribute detailed data on consecutive alloHCTs and autologous HCTs to a statistical center at the Medical College of Wisconsin (Milwaukee, WI) and the NMDP Coordinating Center (Minneapolis, MN). The International Bone Marrow Transplant Registry has been collecting alloHCT data from centers worldwide since 1972, and the Autologous Blood and Marrow Transplant Registry has collected autologous HCT data from centers in North and South America since 1991. Participating centers are required to report all transplantations consecutively; compliance is monitored by onsite audits. Patients are observed longitudinally. Computerized checks for discrepancies, physician review of submitted data, and onsite audits of participating centers ensure data quality. Observational studies conducted by the CIBMTR are performed under the guidance of the institutional review boards of the Medical College of Wisconsin and the NMDP and are in compliance with all applicable federal regulations pertaining to the protection of human research participants.
Study Population
For this study, we selected first alloHCTs performed in the United States or Canada and reported to the CIBMTR between 1994 and 2005. Our final study population consisted of 38,060 patients undergoing first alloHCT performed in the United States or Canada from 1994 to 2005.
Data Collection and Reporting
During the study period, 286 unique transplantation centers contributed data to the CIBMTR. During each of the 12 years in the study period, 109 centers (38%) reported at least one alloHCT to the CIBMTR. Only 70 centers (24%) provided data for less than half of the study period.
The CIBMTR collects data at two levels: transplant-essential data (TED) and comprehensive report form (CRF) data. TED include disease type, age, sex, pretransplantation disease stage and chemotherapy responsiveness, date of diagnosis, graft type (bone marrow-and/or blood-derived stem cells), high-dose conditioning regimen, post-transplantation disease progression and survival, development of new malignancy, and cause of death. All CIB-MTR teams contribute TED. More detailed disease and pre-and posttransplantation clinical information are collected for a subset of registered patients selected for CRF data by a weighted randomization scheme. TED and CRF data are collected before transplantation, 100 days and 6 months after transplantation, and annually thereafter or until death.
For the purpose of this study, to obtain the broadest representation of alloHCT use, CIBMTR TED were used. HLA match was defined by the individual center and varied over time in response to changes in HLA typing during the study period.
9 Karnofsky (KPS)/Lansky performance score was reported as Ͻ 80 or Ն 80.
Statistical Analysis
The cohort was divided into six 2-year time periods to permit description of trends over time. Descriptive statistics, including proportions, medians, and ranges, were calculated. There were no tests of statistical significance for volume data. OS estimates and 95% CIs were calculated at day ϩ100, which primarily represents early transplantation-related mortality (TRM), and at 1 year, which represents disease-related mortality and later TRM. Statistical significance was measured using pointwise P values. OS estimates were determined for a priori defined disease and disease status subgroups and were not adjusted for any patient or disease covariates. Disease status subgroups with significant trends in OS over time were stratified by age to determine the pattern of OS trend by age. To reduce type I error, P Ͻ .01 was considered statistically significant.
Estimation of the Rate of AlloHCT Over Time
Age-specific incidence of six major hematologic disorders (acute lymphoblastic leukemia [ Age-specific intercensal population estimates from 1994 to 2005 were obtained from the US Census Bureau. 18 The number of new patient cases of each disease by age group and year was estimated by applying the age-specific SEER incidence to the US national population in that age group. AlloHCTs for these six major hematologic disorders were actual numbers reported to the CIB-MTR that captured approximately 70% to 90% of related-donor and 90% of unrelated-donor alloHCTs performed at a US transplantation center during the period of 1994 to 2005. Therefore, an inflation factor of 1.11 was applied to the reported unrelated-donor alloHCTs and an inflation factor of 1.15 to 1.43 was applied to the reported related-donor alloHCTs to account for variances in the proportion of all alloHCTs performed in the United States that were reported to the CIBMTR. The rate of alloHCT for each disease was calculated by dividing the number of alloHCTs (after applying the inflation factor) by the number of newly diagnosed patients, excluding incident patient cases and alloHCTs for those age Ն 75 years and excluding alloHCTs performed in Canada.
RESULTS
Patient Characteristics
Characteristics of patients who underwent alloHCT are summarized in Table 1 . Each of the 2-year cohorts experienced an increase in alloHCT volume over the prior 2-year cohort. The number of transplantation centers with active reporting in any 2-year period ranged from 143 to 161. Median age increased over the study period (from 33 years in 1994 to 1995 to 40 years in 2004 to 2005). Although the number of patients undergoing alloHCT age Ն 60 years increased, these patients comprise only 10% of all alloHCTs performed. There was improvement in the collection of KPS over the entire study period, with 47% missing data in the period of 1994 to 1995 and 13% missing data in the period of 2004 to 2005. Because of the large amount of incomplete data on KPS for most of the study period, it was difficult to assess changes in patient characteristics over time. Similarly, between 1997 and 1998, there was improvement in completeness of data collected for race. Since 1998, the proportion of alloHCTs for nonwhite races/ethnicities remained stable. The number of alloHCTs per- 
Disease Indications and Transplantation Types
A majority of alloHCTs performed in 1994 to 1995 were for AML (25%), chronic myeloid leukemia (CML; 23%), and ALL (18%). Since 2000, there has been a decrease in the number of alloHCTs performed 
Use of AlloHCT Over Time
The rate of alloHCT over time is summarized in Table 2 . The US population age 0 to 74 years increased by 10.6% between 1994 and 2005. For AML, the incident rate in those age 0 to 74 years decreased by 10%, whereas the number of incident patient cases increased by 2%, and the rate of alloHCT for AML increased by 56% over this time, from 12.4% to 19.3%. For ALL, the incident rate in those age 0 to 74 years increased by 14%, and the number of incident patient cases increased by 18%, with a relatively stable rate of alloHCT for ALL at 12.3% to 13.8%. For NHL, the incident rate remained stable, and the number of incident patient cases increased by 10.3%, which corresponds to the increase in the US population; however, the rate of alloHCT for NHL increased by 66% during this time, from 0.6% to 1.0%. For HL, the incident rate increased by 4%; the number of incident patient cases increased by 15%, which exceeds the increase in the US population; and the rate of alloHCT for HL increased by 50% during this time, from 0.4% to 0.6%. For MM, the incident rate increased by 8%, and the number of incident cases increased by 20%, which exceeds the increase in the US population; however, the rate of alloHCT for MM decreased by 82% during this time, from 1.7% to 0.3%.
OS After HLA-Matched Sibling-Donor AlloHCT
In every disease group that received a myeloablative conditioning regimen, OS at 100 days after HCT demonstrated statistically significant increases over time (Table 3) . In all age groups, OS estimates at day ϩ100 after alloHCT in the most recent cohort (2004 to 2005) ranged from 88% in patients with MDS to 98% in patients with CML undergoing transplantation in first chronic phase. Even in older patients age 40 to 59 years at time of HCT, OS estimates at day ϩ100 after alloHCT were 89% for those with AML in first complete remission (CR1), 84% for those with CML in first chronic phase, and 86% in those with MDS. Although patients with CML in first chronic phase (all age groups) experienced statistically significant increases in OS 1 year after alloHCT, patients with AML in CR1, ALL in second complete remission (CR2), and MDS had relatively stable 1-year OS estimates of 75%, 70%, and 64%, respectively. For patients with AML, ALL, CML, or MDS who received a reduced-intensity or nonmyeloablative conditioning regimen during the period of 2004 to 2005, the OS estimates at day ϩ100 and 1 year after alloHCT were 77% and 49%, respectively. For those with AML, ALL, CML, or MDS who received a myeloablative conditioning regimen and were age Ն 60 years at time of HLA-matched sibling alloHCT (n ϭ 74), OS estimates at day ϩ100 and 1 year after alloHCT were 81% (95% CI, 71% to 89%) and 40% (95% CI, 28% to 52%) in 2004 to 2005 compared with 67% (95% CI, 54% to 79%) and 35% (95% CI 22% to 48%) in 1996 to 1997, respectively (P not significant for either comparison). OS estimates at day ϩ100 and 1 year after alloHCT for 172 patients with AML, ALL, CML, or MDS age Ն 60 years who received a reducedintensity or nonmyeloablative conditioning regimen during the period of 2004 to 2005 were similar, at 83% (95% CI, 77% to 88%) and 44% (95% CI, 36% to 52%), respectively, and did not change over time.
OS After HLA-Matched Unrelated-Donor AlloHCT
Similar to sibling-donor HCTs, in every disease group that received a myeloablative conditioning regimen before unrelated-donor HCT, OS at 100 days after alloHCT demonstrated statistically significant increases over time ( 
OS After UCB Transplantation With a Myeloablative
Conditioning Regimen OS estimates at day ϩ100 after UCB transplantation significantly improved over time for patients with malignant disease (AML, ALL, CML, or MDS; Table 5 ); however, this improvement was limited to younger patients (age 0 to 19 years). OS estimates at day ϩ100 and 1 year for older patients (age 20 to 39 years) treated for malignant diseases and for all patients treated for nonmalignant diseases showed some improvement but did not significantly differ over time. The number of patients who underwent UCB transplantation using a reduced-intensity or nonmyeloablative conditioning regimen was too small for analysis of OS.
DISCUSSION
We identified some notable trends in the use of alloHCT in North America during the study time period. For instance, introduction of reduced-intensity and nonmyeloablative regimens has resulted in an increased use of alloHCT in older patients. The decrease in alloHCT for CML paralleled the introduction and increasing use of oral tyrosine kinase inhibitors for this disease. A greater proportion of patients with acute leukemia underwent alloHCT in CR in the more recent time period, indicating more timely transplantation among patients who were referred for alloHCT. Better understanding of the disease risk profile gained from leukemia clinical trials has likely contributed to early referral for alloHCT among patients who have a high probability of relapse with chemotherapy. Finally, the largest increase in alloHCT was attributed to the greater availability of unrelated donors, reflecting the efforts invested by the NMDP in enlarging and diversifying its donor registry.
In the past, alloHCT was associated with high TRM. However, our study, which represents approximately 70% to 90% of all alloHCTs performed in the United States, reinforces others demonstrating significantly improved survival rates over time.
19,20 Although we were
